Skip to search formSkip to main contentSkip to account menu

venetoclax

Known as: 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide, 4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzene-1-sulfonyl)-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide, benzamide, 4-(4-((2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-n-((3-nitro-4-(((tetrahydro-2h-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-2-(1h-pyrrolo(2,3-b)pyridin-5-yloxy)- 
An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax… 
National Institutes of Health

Related topics

Related topics

6 relations

Narrower (2)

ABT-199GDC-0199

Broader (3)

Antineoplastic AgentsBridged Bicyclo Compounds, HeterocyclicSulfonamides
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
COPANLISIB SYNERGIES WITH CONVENTIONAL AND TARGETED AGENTS INCLUDING VENETOCLAX IN PRECLINICAL MODELS OF B‐ AND T‐CELL LYMPHOMAS
Purpose: This study was aimed at evaluating the feasibility, safety, immunological and clinical responses in patients with… 
2019
2019
Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML)
Introduction: Molecular MRD monitoring in NPM1 mutant (mut) AML is now standard of care in many countries as prospective… 
2017
2017
Combination of BR101801 and Venetoclax Demonstrates Synergistic Activity in DLBCL Cell Lines Harboring Double Hit and Double Expressor Alterations
Introduction: Double hit DLBCL with concurrent rearrangement of c-Myc and BCL-2 as well as double expressor DLBCL with… 
2017
2017
Impact of Number of Prior Therapies and Bulk of Disease on Outcomes with Venetoclax (VEN) Monotherapy for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Background: The BCL-2 inhibitorVEN is an effective therapy for patients (pts) with relapsed/refractory (R/R) CLL, including those… 
2017
2017
Abstract 1106: Alvocidib potentiates the activity of venetoclax in preclinical models of multiple myeloma
The proteasome inhibitor bortezomib is widely used in the treatment of patients with multiple myeloma (MM). The expression levels… 
2016
2016
Correlative Biomarkers of Response to Venetoclax in Combination with Chemotherapy or Hypomethylating Agents in Elderly Untreated Patients with Acute Myeloid Leukemia
Background: We recently reported encouraging antileukemic activity of venetoclax, an orally available selective BCL-2 inhibitor… 
2016
2016
Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia
Background: Venetoclax (VEN) is a potent, highly selective, orally bioavailable small-molecular BCL2 inhibitor that is FDA… 
2016
2016
Detailed Safety Analysis of Venetoclax Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Background: Venetoclax (VEN) is a selective, potent, orally bioavailable BCL-2 inhibitor FDA-approved for patients with del(17p… 
2016
2016
Comment on Wang et al , page 2742 Cytogenetics in CML : more important than you think
is a survival-enhancing oncoprotein that is frequently overexpressed in ABC-DLBCL by virtue of gene amplification (focal copy… 
2016
2016
Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients
Introduction: Ibrutinib (Ibr), idelalisib (Ide), andvenetoclax (Ven), are all now approved for treating CLL patients in the US…